Tuesday - July 1, 2025
IMBRUVICA Combination Shows Superior Efficacy in Chronic Lymphocytic Leukaemia
June 12, 2025
NEW BRUNSWICK, New Jersey, June 12 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

Significant efficacy benefit of IMBRUVICA(r) (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison

*

BEERSE, BELGIUM (12 June 2025) - Janssen-Cilag International NV, a Johnson & Johnson . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products